ICER offers final verdict against Biogen's aducanumab: No proof it works, clear prospect of harm, wildly overpriced

John Carroll

Editor & Founder

The folks at ICER have crunched the data on aducanumab. The independent drug watchdog brought together a panel of Alzheimer’s experts to review the trial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ICER offers final verdict against Biogen's aducanumab: No proof it works, clear prospect of harm, wildly overpriced

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

GSK defiant against vaccine challenges, will prioritize other growth areas

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Novo Nordisk sees growth slowing this year, plans CagriSema filing for 2026

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

Drugmakers seize on biomarkers to test the FDA's rare disease shift

ICER of­fers fi­nal ver­dict against Bio­gen's ad­u­canum­ab: No proof it works, clear prospect of harm, wild­ly over­priced

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

ICER offers final verdict against Biogen's aducanumab: No proof it works, clear prospect of harm, wildly overpriced